Centanafadine Hydrochloride(Centanafadine Hydrochloride) - 药物靶点：DAT x NET x SERT_在研适应症：注意缺陷障碍伴多动，广泛性焦虑障碍，重度抑郁症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Centanafadine、Centanafadine hydrochloride (USAN)、Centanafadine SR

+ [10]

靶点

DAT x NET x SERT

作用方式

抑制剂

作用机制

多巴胺重摄取抑制剂、NET抑制剂(去甲肾上腺素转运蛋白抑制剂)、5-羟色胺重摄取抑制剂

治疗领域

其他疾病神经系统疾病

在研适应症

注意缺陷障碍伴多动广泛性焦虑障碍重度抑郁症

非在研适应症

注意缺陷障碍暴食症尼古丁成瘾

原研机构

Euthymics Bioscience, Inc.

在研机构

Otsuka Pharmaceutical Development & Commercialization, Inc.

Kanae Co., Ltd.

Otsuka Pharmaceutical Co., Ltd.

+ [1]

非在研机构

Neurovance, Inc.

权益机构-

最高研发阶段申请上市

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评优先审评 (美国)

登录后查看时间轴

结构/序列

分子式C15H16ClN

InChIKeyACVMJAJGCQUPKX-LIOBNPLQSA-N

CAS号923981-14-0

关联

25

项与 Centanafadine Hydrochloride 相关的临床试验

NCT07314333

/ Not yet recruiting临床1期

A Phase 1, Single Blind, Parallel-arm Trial to Assess the Potential for Pharmacodynamic Interaction of Centanafadine When Co-administered With Stimulants in Healthy Adults

This study will look at how centanafadine works when taken together with stimulant medicines in healthy adults, and whether combining them affects how the body responds.

开始日期2026-02-03

申办/合作机构

Otsuka Pharmaceutical Development & Commercialization, Inc.

NCT07087327

/ Recruiting临床3期

A Phase 3, Multicenter, Open-label, Uncontrolled, Long-term Japan-China Joint Trial to Evaluate the Safety and Efficacy of EB-1020 QD XR Capsules Administered Orally Once Daily in Children and Adolescents With Attention- Deficit/Hyperactivity Disorder

The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in pediatric ADHD patients.

开始日期2025-09-16

申办/合作机构

Otsuka Pharmaceutical Co., Ltd.

NCT07086313

/ Recruiting临床2/3期

A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Japan-China Joint Trial to Evaluate the Efficacy and Safety of Two Dose Levels of EB-1020 QD XR Capsules Administered Orally Once Daily in Children and Adolescents With Attention-deficit/Hyperactivity Disorder

The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in pediatric ADHD patients.

开始日期2025-09-03

申办/合作机构

Otsuka Pharmaceutical Co., Ltd.

100 项与 Centanafadine Hydrochloride 相关的临床结果

登录后查看更多信息

100 项与 Centanafadine Hydrochloride 相关的转化医学

登录后查看更多信息

100 项与 Centanafadine Hydrochloride 相关的专利（医药）

登录后查看更多信息

25

项与 Centanafadine Hydrochloride 相关的文献（医药）

2026-01-01·CTS-Clinical and Translational Science

Measurement of Centanafadine Concentrations in a Pharmacokinetic Trial: Comparison of Traditional Venipuncture Versus Blood Microsampling

Article

作者: Wang, Yanlin ; Westcott‐Baker, Lucas ; Chung, Chris ; Roth, Sharin E.

ABSTRACT:

In clinical pharmacology trials, pharmacokinetic samples are typically collected via venipuncture by trained staff. However, recent advances in blood collection devices have enabled participant self‐collection of samples. Here, we describe the feasibility of collecting dried blood from healthy volunteers using a microsampling device by comparing centanafadine concentrations from self‐collected microsamples with those collected via venipuncture by phlebotomists in an exploratory phase 1 pharmacokinetic trial. High‐performance liquid chromatography with tandem mass spectrometric (HPLC‐MS/MS) bioanalytical methods were validated for both dried blood collected via microsampling and plasma, with all validation criteria successfully met. Concordance between venous and microsamples was evaluated using graphical analysis and Deming regression, based on data from two conventional phase 1 trials (samples collected by clinical staff) and an exploratory pharmacokinetic trial comparing staff‐collected venous samples (visits 1 and 2) with microsamples collected by staff (visit 1) or self‐collected by participants (visits 2 and 4). Deming regression revealed significant linear relationships between centanafadine concentrations from venous and dried blood samples in conventional trials, and between microsamples at visits 2 and 4 versus visit 1 in the exploratory pharmacokinetic trial (visit 2: self‐collected under supervision, slope = 1.135; visit 4: self‐collected at home, slope = 0.967). The bioanalytical method used for the measurement of centanafadine concentrations in dried blood collected by the microsampling device was successfully validated, and feasibility assessments resulted in concordance suggesting that it is suitable to collect centanafadine pharmacokinetic samples at home during the conduct of self‐collection phase 1 pharmacokinetic trials.

2025-11-01·JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY

Editorial: Centanafadine for Adolescents With Attention-Deficit/Hyperactivity Disorder: Is a Broader Mechanism of Action Better?

作者: Stein, Mark A

Attention-deficit/hyperactivity disorder (ADHD) is among the most prevalent disorders in adolescents. A recent survey found that 13.6% of 12- to 17-year-olds in the United States have a diagnosis of ADHD.¹ Many children who are diagnosed with ADHD continue to meet ADHD diagnostic criteria as teenagers; other youth are diagnosed later due to a variety of factors, including prominent comorbid conditions, stigma, and limited awareness or detection in youth who show only inattention. More than half of adolescents with ADHD are treated with medication, with many receiving medication alone. Multimodal treatment is recommended because of the complementary benefits of pharmacotherapy on core ADHD symptoms and cognitive-behavioral interventions that target impairments.² Compared with children, maintenance of pharmacotherapy is more difficult in adolescents due to nonadherence or early discontinuation.^3-5 As a result, a new medication with an improved risk-to-benefit ratio, especially one that addresses more than core ADHD symptoms and adolescent-specific issues, represents a significant advance.

2025-10-13·EXPERT OPINION ON PHARMACOTHERAPY

Potential treatments for attention-deficit/hyperactivity disorder: a focus on Phase III trials

Review

作者: Bilgic, Ayhan ; Ferahkaya, Hurşit

INTRODUCTION:

Stimulant medications, such as methylphenidate and amphetamine derivatives, and non-stimulant medications, such as atomoxetine, guanfacine, clonidine, and viloxazine, are considered the cornerstones of pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD). However, a significant number of individuals respond partially to these treatments or are concerned about side effects. This creates a need for new treatment strategies that target alternative neurobiological mechanisms and offer improved tolerability and efficacy profiles.

AREA COVERED:

This review examines pharmacological agents currently in phase III clinical development or recently completed trials for the treatment of ADHD. We highlight four promising candidates: centanafadine, solriamfetol, CTx-1301, and NRCT-101SR. We discuss their pharmacological mechanisms, clinical efficacy, safety profiles, and regulatory status, with an emphasis on how these agents may address existing therapeutic gaps and the potential clinical implications. A literature search was conducted using PubMed and ClinicalTrials.gov databases for articles published between January 2018-July 2025.

EXPERT OPINION:

Recent advances in ADHD pharmacotherapy suggest that approaches targeting monoaminergic systems beyond dopamine and noradrenaline reuptake inhibition may provide therapeutic benefits. Additionally, multi-phase extended-release formulations may improve adherence and enhance symptom control throughout the day. As phase III data become available, these agents have the potential to redefine ADHD treatment paradigms.

21

项与 Centanafadine Hydrochloride 相关的新闻（医药）

2026-01-28

·Pharmaceutical Technology

FDA accepts Otsuka’s centanafadine application for ADHD treatment

Centanafadine showed significant improvements in ADHD symptoms compared with placebo. Credit: Inna Kot / Shutterstock.com. The US Food and Drug Administration (FDA) has accepted for priority review Otsuka Pharmaceutical’s new drug application (NDA) submitted for centanafadine, an investigational, once-daily extended-release capsule for attention-deficit hyperactivity disorder (ADHD) treatment. Otsuka’s NDA covers the use of centanafadine as a treatment for ADHD in adolescents, adults, and children. Centanafadine is a norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). The Prescription Drug User Fee Act (PDUFA) target action date for the NDA is scheduled for 24 July 2026. The application is supported by findings from four pivotal Phase III trials assessing the safety and efficacy across various age groups. In these trials, centanafadine showed significant improvements in ADHD symptoms compared with placebo, using the ADHD Investigator Symptom Rating Scale in adults, and the ADHD Rating Scale-5 in adolescents and children. Centanafadine was found to be generally well-tolerated during the trials. The most common adverse events reported among adolescents and children included abdominal pain, decreased appetite, fatigue, nausea, rash, and somnolence. For adults, headache and decreased appetite were observed. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Otsuka development and commercialisation executive vice-president and chief medical officer John Kraus said: “ADHD manifests differently across patients, highlighting the importance of having multiple therapeutic approaches available. “The FDA’s acceptance and priority review designation of our NDA for centanafadine marks an important milestone in our effort to bring forward a novel treatment option for people living with ADHD. “If approved, centanafadine would offer a first-in-class NDSRI option designed to support broad symptom management. We extend our sincere gratitude to the patients, caregivers, and investigators whose participation made this milestone possible.” In November 2025, Otsuka secured accelerated approval from the FDA for Voyxact (sibeprenlimab-szsi) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at disease progression risk.

申请上市临床3期临床结果优先审批免疫疗法

2026-01-27

·药明康德

产业新闻 | 抗癌小分子获突破性疗法认定，上市申请即将完成；潜在“first-in-class”小分子获FDA优先审评资格……

抗癌小分子获突破性疗法认定，上市申请递交即将完成！ Cogent Biosciences日前宣布，美国FDA授予其在研小分子bezuclastinib联合sunitinib突破性疗法认定（BTD），用于治疗既往接受过imatinib治疗的胃肠道间质瘤（GIST）患者。公司同时表示，拟将PEAK临床试验结果作为bezuclastinib新药申请（NDA）的重要组成部分提交至FDA，并计划于2026年4月完成相关递交工作。 BTD的授予主要基于PEAK临床试验结果。分析显示，该试验在主要终点无进展生存期（PFS）上取得了具有高度统计学意义的临床获益。与sunitinib单药治疗相比，bezuclastinib联合方案将疾病进展或死亡风险降低了50%，风险比为0.50（95% CI：0.39–0.65）。经盲法独立中央评审评估，联合治疗组的中位PFS为16.5个月，而单药组为9.2个月。此外，该联合方案整体耐受性良好，与sunitinib既有安全性特征相比未观察到新的安全性风险。 Bezuclastinib是一种选择性酪氨酸激酶抑制剂，旨在强效抑制KIT基因中关键驱动突变产生的突变蛋白活性。其中一种突变KIT D816V会驱动系统性肥大细胞增多症，这是一种由肥大细胞失控增殖引起的严重疾病。其他KIT突变，包括发生在第17外显子上的多种突变，则会驱动GIST患者的肿瘤生长。潜在“first-in-class”小分子获FDA优先审评资格大冢制药（Otsuka Pharmaceutical）今日宣布，美国FDA已受理其在研药物centanafadine的新药申请，并授予优先审评资格。Centanafadine是一款每日一次给药的缓释胶囊，为潜在“first-in-class”的去甲肾上腺素、多巴胺和5-羟色胺再摄取抑制剂（NDSRI），拟用于治疗儿童、青少年及成人注意缺陷多动障碍（ADHD）。该NDA的PDUFA日期为2026年7月24日。该NDA的递交主要基于四项关键性3期临床试验结果，这些试验评估了centanafadine在不同患者人群中的疗效与安全性。数据显示，与安慰剂相比，centanafadine在改善ADHD症状方面取得了具有统计学显著性且具临床意义的疗效：在青少年和儿童患者中，主要通过ADHD评分量表-5（ADHD-RS-5）进行评估，在成人患者中则通过ADHD研究者症状评分量表（AISRS）进行评估。此外，centanafadine在各项研究中整体耐受性良好，儿童和青少年中最常见的不良事件包括食欲减退、恶心、皮疹、乏力、腹痛和嗜睡，而成人中较常见的不良事件为食欲减退和头痛。新锐走出隐匿模式，即将启动潜在“best-in-class”疗法3期试验 Baseline Therapeutics今日宣布公司走出隐匿模式。该公司致力于推进新一代用于物质使用障碍的药物治疗方案。公司当前的核心项目BT-001是一款潜在“best-in-class”、每周给药一次的GLP-1受体激动剂（GLP-1RA）候选药物，用于治疗酒精使用障碍（AUD），并计划在此基础上拓展至其他物质使用障碍适应症。值得注意的是，BT-001在代谢性疾病领域已积累了丰富的人体研究经验，覆盖超过10项临床试验和数千名受试者，为其良好的安全性特征提供了有力支持。在开发计划方面，Baseline Therapeutics表示，拟于2026年启动两项随机、安慰剂对照的3期临床试验，系统评估BT-001在酒精使用障碍患者中的疗效与安全性。参考资料： [1] Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST). Retrieved January 27, 2026 from https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-breakthrough-therapy-designation [2] Otsuka Announces FDA Acceptance and Priority Review of New Drug Application for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults. Retrieved January 27, 2026 from https://www.businesswire.com/news/home/20260127432877/en/Otsuka-Announces-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-Centanafadine-for-the-Treatment-of-ADHD-in-Children-Adolescents-and-Adults [3] Baseline Therapeutics Launches to Advance GLP-1RA Phase 3 Program in Alcohol Use Disorder. Retrieved January 27, 2026 from https://www.businesswire.com/news/home/20260127759694/en/Baseline-Therapeutics-Launches-to-Advance-GLP-1RA-Phase-3-Program-in-Alcohol-Use-Disorder 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

2026-01-27

·Business Wire

Otsuka Announces FDA Acceptance and Priority Review of New Drug Application for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for centanafadine, an investigational, once-daily extended release capsule and the first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit hyperactivity disorder (ADHD) in children, adolescents, and adults. The Prescription Drug User Fee Act (PDUFA) target action date is set for July 24, 2026. The NDA is supported by results from four pivotal Phase 3 clinical trials evaluating the efficacy and safety of centanafadine across patient populations1,2,3. In these trials, centanafadine demonstrated statistically significant and clinically meaningful improvements in ADHD symptoms compared with placebo, as measured by the ADHD Rating Scale – 5 (ADHD-RS-5) in adolescents and children, and the ADHD Investigator Symptom Rating Scale (AISRS) in adults. Centanafadine was generally well tolerated across studies, with the most common adverse events including decreased appetite, nausea, rash, fatigue, abdominal pain, and somnolence in children and adolescents, and decreased appetite and headache in adults1,2,3. “ADHD manifests differently across patients, highlighting the importance of having multiple therapeutic approaches available,” said John Kraus, M.D., Ph.D., executive vice president and chief medical officer, Otsuka Pharmaceutical Development & Commercialization, Inc. “The FDA’s acceptance and priority review designation of our NDA for centanafadine marks an important milestone in our effort to bring forward a novel treatment option for people living with ADHD. If approved, centanafadine would offer a first-in-class NDSRI option designed to support broad symptom management. We extend our sincere gratitude to the patients, caregivers, and investigators whose participation made this milestone possible.” Although historically seen as a childhood disorder, research suggests that many individuals diagnosed with ADHD in childhood continue to experience symptoms into adulthood, with some patients experiencing significant impairment. About Attention-Deficit Hyperactivity Disorder (ADHD) ADHD is a chronic neurodevelopmental disorder characterized primarily by impairments in attention, hyperactivity, and impulsivity4. It affects approximately 7 million children in the U.S. and an estimated 15.5 million adults, according to the Centers for Disease Control and Prevention (CDC)5,6. About Centanafadine Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). Clinical studies have shown that centanafadine significantly reduces core symptoms of ADHD in children, adolescents, and adults. Clinical and preclinical data suggest centanafadine showed a favorable safety and tolerability profile and low potential for abuse. About Otsuka Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: Otsuka–people creating new products for better health worldwide. Otsuka researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health. In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, kidney, and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does. Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These two companies’ 2,250 employees in the U.S. develop and commercialize medicines in the areas of mental health and nephrology, using cutting-edge technology to address unmet healthcare needs. OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Co., Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 35,340 people worldwide and had consolidated sales of approximately USD 14.7 billion in 2024. All Otsuka stories start by taking the road less traveled. Learn more about Otsuka in the U.S. at www.otsuka-us.com and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.’s global website is accessible at https://www.otsuka.co.jp/en/. References Ward, Caroline L., et al. “Efficacy and safety of centanafadine for ADHD treatment in children: A randomized clinical trial.” Pediatrics Open Science , vol. 1, no. 3, 1 July 2025, pp. 1–11, https://doi.org/10.1542/pedsos.2024-000349 . Ward, Caroline L., Ann C. Childress, et al. “Centanafadine for attention-deficit/hyperactivity disorder in adolescents: A randomized clinical trial.” Journal of the American Academy of Child & Adolescent Psychiatry , July 2025, https://doi.org/10.1016/j.jaac.2025.06.023 . Adler, Lenard A., et al. “Efficacy, safety, and tolerability of Centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder.” Journal of Clinical Psychopharmacology , vol. 42, no. 5, 2 June 2022, pp. 429–439, https://doi.org/10.1097/jcp.0000000000001575 . American Psychiatric Association (2022). Diagnostic and Statistical Manual of Mental Disorders (5 th ed., text rev). “Data and Statistics on ADHD.” Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, www.cdc.gov/adhd/data/index.html . “Facts about ADHD in Adults.” Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, www.cdc.gov/adhd/php/adults/ . JANUARY 2026 26US25EBC0003

临床3期申请上市临床结果优先审批

100 项与 Centanafadine Hydrochloride 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10698	Centanafadine Hydrochloride	-	DB14841

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
注意缺陷障碍伴多动	申请上市	美国	Otsuka Holdings Co., Ltd.	2025-11-25
广泛性焦虑障碍	临床3期	美国	Otsuka Pharmaceutical Development & Commercialization, Inc.	2025-03-26
注意缺陷障碍	临床3期	美国	Otsuka Pharmaceutical Development & Commercialization, Inc.	2019-01-16
重度抑郁症	临床2期	美国	Otsuka Pharmaceutical Development & Commercialization, Inc.	2022-09-12
暴食症	临床2期	美国	Otsuka Pharmaceutical Development & Commercialization, Inc.	2021-12-16
尼古丁成瘾	临床2期	美国	Otsuka Pharmaceutical Development & Commercialization, Inc.	2021-09-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05113953 (CTgov)	临床2期	暴食症	147	Centanafadine (Centanafadine 400 mg)	壓鏇製遞鏇構醖蓋獵製(壓襯積醖構襯製餘襯製) = 獵窪窪衊範鹽鑰鹹觸顧觸顧製選膚網鹽窪醖廠 (淵齋壓築繭顧壓憲淵齋, 0.23) 更多	-	2025-09-09
				Placebo+Centanafadine (Centanafadine 200 mg)	壓鏇製遞鏇構醖蓋獵製(壓襯積醖構襯製餘襯製) = 觸積膚構鹽窪構襯鹽夢觸顧製選膚網鹽窪醖廠 (淵齋壓築繭顧壓憲淵齋, 0.23) 更多
NCT05257265 (A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention-Deficit/Hyperactivity Disorder, Pubmed \| J Am Acad Child Adolesc Psychiatry)	临床3期	注意缺陷障碍伴多动	459	Centanafadine 164.4 mg	憲築選鏇觸製憲憲簾繭(鑰鹹築構鹽蓋鹽廠壓鬱) = 1 event in 164.4 mg group 糧鏇觸醖積鬱鏇顧蓋築 (鏇觸艱襯構鬱襯積鏇繭 ) 更多	积极	2025-07-01
				Centanafadine 328.8 mg
NCT05066724 (CTgov)	临床2期	尼古丁成瘾	50	Centanafadine	鏇顧衊艱簾顧膚淵遞鏇 = 簾襯壓鬱鑰網鹹遞鹽鹽淵遞膚觸廠醖製觸製願 (蓋願衊襯廠簾願淵廠艱, 構夢觸獵範範遞顧積齋 ~ 糧壓鹽憲鹹繭衊齋獵夢) 更多	-	2025-06-13
NCT03605849 (CTgov)	临床3期	注意缺陷障碍	662	Centanafadine SR (Prior Centanafadine SR 200 mg)	願膚繭壓糧鏇構鹽顧鹽 = 襯簾廠網糧窪鬱醖構壓夢顧餘餘積淵壓窪齋廠 (蓋鹹鏇衊夢壓鹹壓壓顧, 襯鬱顧簾鬱衊繭壓夢鹹 ~ 鑰鹽襯簾顧襯築襯鑰襯) 更多	-	2024-10-01
				Centanafadine SR (Prior Centanafadine SR 400 mg)	願膚繭壓糧鏇構鹽顧鹽 = 夢鏇艱夢廠鹽膚膚憲簾夢顧餘餘積淵壓窪齋廠 (蓋鹹鏇衊夢壓鹹壓壓顧, 淵醖糧壓範獵糧淵糧選 ~ 鏇積觸廠簾糧願淵餘淵) 更多
NCT00334880 \| NCT03605836 \| NCT00190736 \| NCT04016779 (Pubmed)	N/A	注意缺陷障碍伴多动	-	Centanafadine sustained-release	餘鑰構簾簾壓鹽構網簾(網襯遞夢衊願構夢膚遞) = 6.58-point difference 觸遞襯範衊鑰醖鑰齋範 (積鹹獵顧製醖廠網淵構 )	积极	2024-06-01
NCT05428033 (NEWS) 人工标引	临床3期	注意缺陷障碍伴多动	-	Centanafadine (high dose)	糧餘顧繭憲遞廠顧壓壓(窪窪壓醖憲簾鑰衊廠窪) = In a pooled analysis across the two studies, the most frequently observed side effects for centanafadine (>2 percent and more frequent than placebo) included decreased appetite, nausea, rash, fatigue, upper abdominal pain and somnolence.Overall, the safety and tolerability results were consistent with the profile of centanafadine seen within the wider clinical development program. 糧襯膚蓋憲艱鹽鑰顧簾 (製鏇鹹鹽糧膚鬱襯窪鏇 )	积极	2023-10-27
				Centanafadine (low dose)
NCT05257265 (NEWS) 人工标引	临床3期	注意缺陷障碍伴多动	-	Centanafadine (high dose)	廠觸觸範餘壓獵壓遞餘(膚齋繭範鹽蓋鑰鹽醖壓) = In a pooled analysis across the two studies, the most frequently observed side effects for centanafadine (>2 percent and more frequent than placebo) included decreased appetite, nausea, rash, fatigue, upper abdominal pain and somnolence.Overall, the safety and tolerability results were consistent with the profile of centanafadine seen within the wider clinical development program. 網製醖窪餘範鏇廠顧淵 (齋獵鹹範選構鑰艱鹽糧 )	积极	2023-10-27
				Centanafadine (low dose)
NCT04081363 (CTgov)	临床2期	注意缺陷障碍伴多动	13	Centanafadine (Swallowed Capsules Cohort)	淵餘積遞壓醖願製繭鬱(餘淵壓製製壓簾鏇餘鏇) = 膚鬱製鹹簾簾範顧齋鏇遞獵鏇製築壓鹽範網鑰 (廠膚獵選鹽繭範製夢獵, 51.4) 更多	-	2023-01-13
				Centanafadine (Sprinkled Onto Applesauce Cohort)	淵餘積遞壓醖願製繭鬱(餘淵壓製製壓簾鏇餘鏇) = 製範網選衊齋夢鹹鹹鑰遞獵鏇製築壓鹽範網鑰 (廠膚獵選鹽繭範製夢獵, 52.8) 更多
NCT03605836 (CTgov)	临床3期	注意缺陷障碍	590	Centanafadine SR (Double-blind Treatment Period: Centanafadine SR 200 mg)	鑰構廠壓積鬱觸艱襯選(繭淵鹽鹹齋構築簾製餘) = 簾繭網餘鏇積範夢蓋淵憲夢繭窪鑰鹽廠顧鬱窪 (窪顧觸願鹽鏇襯蓋獵鹹, 0.96) 更多	-	2021-10-18
				Centanafadine SR (Double-blind Treatment Period: Centanafadine SR 400 mg)	鑰構廠壓積鬱觸艱襯選(繭淵鹽鹹齋構築簾製餘) = 鹽獵廠齋膚鑰觸淵範糧憲夢繭窪鑰鹽廠顧鬱窪 (窪顧觸願鹽鏇襯蓋獵鹹, 0.99) 更多
NCT01939353 (CTgov)	临床2期	注意缺陷障碍伴多动	45	Placebo+CTN SR	窪壓積鬱積獵鹹選膚範(糧艱製獵蓋構齋鑰醖網) = 積醖齋顧憲膚積願膚築憲構艱艱觸糧構壓鹹範 (觸憲築鬱選顧鏇製遞廠, 6.19) 更多	-	2021-10-18